Journey Medical Co. (NASDAQ:DERM) Short Interest Update

Journey Medical Co. (NASDAQ:DERM) was the target of a significant growth in short interest in January. As of January 31st, there was short interest totalling 83,800 shares, a growth of 6.5% from the January 15th total of 78,700 shares. Currently, 0.8% of the shares of the stock are short sold. Based on an average daily volume of 80,800 shares, the short-interest ratio is presently 1.0 days.

Journey Medical Price Performance

Shares of DERM stock traded down $0.10 during trading hours on Tuesday, reaching $5.14. The company had a trading volume of 39,963 shares, compared to its average volume of 56,683. Journey Medical has a 12-month low of $2.85 and a 12-month high of $6.89. The company has a market capitalization of $107.37 million, a price-to-earnings ratio of -5.47 and a beta of 1.03. The stock has a fifty day moving average of $4.44 and a 200-day moving average of $5.04. The company has a debt-to-equity ratio of 1.81, a quick ratio of 1.03 and a current ratio of 1.38.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Nwam LLC acquired a new position in Journey Medical in the third quarter valued at approximately $59,000. Kovitz Investment Group Partners LLC acquired a new position in Journey Medical during the third quarter worth $66,000. Cetera Investment Advisers lifted its stake in Journey Medical by 21.8% during the fourth quarter. Cetera Investment Advisers now owns 13,839 shares of the company’s stock worth $54,000 after purchasing an additional 2,478 shares in the last quarter. Dimensional Fund Advisors LP acquired a new position in Journey Medical during the fourth quarter worth $80,000. Finally, Citadel Advisors LLC acquired a new position in Journey Medical during the fourth quarter worth $174,000. 7.25% of the stock is currently owned by institutional investors and hedge funds.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.